Protocol Ledger

NCT06093841 · Phase II · ACTIVE NOT RECRUITING

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Interventional Phase II clinical trial protocol NCT06093841 sponsored by Shanghai Ming Ju Biotechnology Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-03 Enrollment: 46 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06093841
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)46 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06093841
Protocol FieldVerified Registry Value
NCT IdentifierNCT06093841
Consolidated Lead SponsorShanghai Ming Ju Biotechnology Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment46 participants (ESTIMATED)
Registered Start Date2023-11-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI